[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rheumatic-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rheumatic-arthritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,137,164,192,220,246],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100626987","intervention-to-support-partners-and-informal-caregivers-of-frail-ra-patients-100626987",false,"NCT07442773","Intervention to Support Partners and Informal Caregivers of Frail RA-patients","Protocol for the Feasibility Study of INSPIRE: an Individually Tailored Support Intervention for Informal Caregivers of Older Adults With Rheumatoid Arthritis and Frailty","INSPIRE","Inclusion Criteria (Caregivers):\n\n* Informal (unpaid) caregiver of an older adult with confirmed rheumatoid arthritis (RA)\n* Aged ≥ 18 years\n* Care recipient aged ≥ 65 years\n* Able to provide informed consent\n* Able to complete study questionnaires\n* Reports at least moderate caregiver burden, defined as mean CBS score \\> 1.99 at screening (Caregiver Burden Scale)\n\nInclusion Criteria (Care Recipients):\n\n* Aged ≥ 65 years\n* Confirmed diagnosis of RA\n* Meets frailty eligibility in routine care, defined as Clinical Frailty Scale (CFS) ≥ 5\n\nExclusion Criteria (Caregivers):\n\n* Severe cognitive impairment preventing participation\n* Acute mental health crisis\n* Other circumstances making it impracticable to complete the intervention and follow-up assessments","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with pain, fatigue, functional limitations, and reduced quality of life. As more people live to older age with RA, age-related vulnerability such as frailty becomes increasingly relevant and may amplify functional decline, multimorbidity, and reliance on others. Informal caregivers (unpaid family members, friends, or neighbors) often provide substantial practical, emotional, and coordination support, yet caregiver needs are frequently overlooked in rheumatology care. INSPIRE (INtervention to Support Partners and Informal caREgivers of frail RA patients) is an individually tailored support intervention developed using the UK Medical Research Council framework for complex interventions and an iterative co-creation process involving older adults with RA and frailty, caregivers, healthcare professionals, and social care stakeholders. Before a definitive evaluation, feasibility and acceptability in routine care must be established.\n\nAim To evaluate the feasibility and acceptability of delivering INSPIRE in routine rheumatology care and to test study procedures in preparation for a future definitive trial.\n\nMethods This is a single-arm feasibility study recruiting 25 informal caregivers of older adults with RA and frailty. Recruitment will occur within a fixed four-month window (1 March-1 July 2026) and will not be extended. Care recipients (older adults) will be ≥65 years with RA and frailty classified as Clinical Frailty Scale (CFS) 4-7. Caregivers will be ≥18 years, provide unpaid support, and report at least moderate burden defined as a Caregiver Burden Scale (CBS) mean score \\>1.99 at screening. Participants will be recruited from Rigshospitalet (Center for Rheumatology and Spine Diseases) and rheumatology departments in Køge, Slagelse, and Holbæk. Identification uses routine patient-reported outcomes (DANBIO) with invitation of potentially frail patients (e.g., MDHAQ \\>1.0) followed by telephone screening and CFS assessment; eligible patients nominate a caregiver who is then screened using CBS.\n\nIntervention INSPIRE is delivered by a trained healthcare professional over \\~12 weeks and comprises three contacts: an initial consultation (60-90 min), a brief follow-up (15-30 min), and a final consultation (30-60 min). Content is tailored using a toolbox addressing validation of the caregiver role, emotional\u002Fpractical support, education, communication, and navigation across health and municipal services. Involvement of the older adult in consultations is optional and based on preferences of both parties.\n\nOutcomes Feasibility outcomes include recruitment (screened\u002Feligible\u002Fconsented), retention at 12 weeks, questionnaire completeness, and deliverability (session completion, mode, duration). Acceptability will be assessed post-intervention using the Acceptability of Intervention Measure and supplemented by brief acceptability\u002Ffeasibility questions and qualitative interviews. Fidelity and tailoring will be documented using structured session notes. Exploratory outcomes include caregiver burden measured by Caregiver burden scale, quality of life measured by WHOQOL-BREF (caregiver and older adult), and physical function measured by MDHAQ .\n\nProgression criteria Pre-specified criteria include approximately 50% recruitment of those approached, ≥85% retention, and high fidelity, reviewed using a trafficlight approach (go\u002Famend\u002Fstop).\n\nEthics and dissemination Written informed consent will be obtained from both the older adult and the caregiver prior to baseline data collection, with separate consent for any study components each participant takes part in (e.g., consultations, interviews). Findings will be disseminated through peer-reviewed publication, conferences, and stakeholder summaries.",[27],"Rheumatic Arthritis",[29,30,31,32,33],"Frailty","RA","older adults","caregivers","support","RECRUITING","2026-03-16",{"date":37,"type":38},"2026-03-17","ACTUAL",{"date":40,"type":38},"2026-03-15",{"date":42,"type":21},"2027-12-01",{"name":44,"class":45},"Glostrup University Hospital, Copenhagen","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":105,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":46},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform",true,"2 Years",{"count":57,"type":21},10000,"10 Years","OBSERVATIONAL","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[62,63,27,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[81,106,107,108,109,110,111,112,113,114,63,115,116,117,118,119,83,120,121,122,123,124,125,126,127],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","2026-01-20",{"date":130,"type":38},"2026-01-22",{"date":132,"type":38},"2023-07-05",{"date":134,"type":21},"2030-12-31",{"name":136,"class":45},"Brain Inflammation Collaborative",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":46},"100590277","study-on-the-detection-of-pleuropulmonary-manifestations-in-rheumatoid-arthritis-100590277","NCT06965322","Study on the Detection of Pleuropulmonary Manifestations in Rheumatoid Arthritis","Prospective Observational Study on the Detection of Pleuropulmonary Manifestations in Rheumatoid Arthritis","REASSESS","Inclusion Criteria:\n\n* Patients ≥18 years diagnosed with rheumatoid arthritis according to current ACR\u002FEULAR criteria\n* Residence in Austria\n* Signed and dated consent of the patient in accordance with ICH-GCP guidelines\n\nExclusion Criteria:\n\n* pregnancy\n* age below 18 years\n* Contraindications to study-related routine examinations (e.g., inability to draw blood due to needle phobia, no CT scan possible due to claustrophobia, pregnancy, etc.)",{"count":146,"type":21},800,"The aim of the study is to develop a standardized, risk-adapted screening protocol for detecting pleuropulmonary manifestations in patients with rheumatoid arthritis. To assess the risk of these manifestations, a comprehensive range of functional and clinical evaluations will be performed and correlated with structural lung assessments using computed tomography (CT).",[27,149],"Interstitial Lung Disease in Patients With Rheumatoid Arthritis",[151,152,153,154],"rheumatoid arthritis","interstitial lung disease","risk prediction","RA-ILD","2025-12-01",{"date":157,"type":38},"2025-12-02",{"date":159,"type":38},"2024-11-11",{"date":161,"type":21},"2029-09-30",{"name":163,"class":45},"Medical University Innsbruck",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":46},"100599814","efficacy-and-safety-of-resveratrol-in-patients-with-rheumatoid-arthritis-100599814","NCT07089381","Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.","Inclusion Criteria:\n\n* Adult patients \\> 18 years old\n* Established diagnosis of RA according to American College of Rheumatology\u002FEuropean league Against Rheumatism (ACR\u002FEULAR) 2010 criteria (Aletaha et al., 2010), presented with moderate to high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n* Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months.\n* RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n\nExclusion Criteria:\n\n* Patients receiving biologic DMARDs therapy for RA\n* Patients taking any other anti-inflammatory drugs\n* Patients taking any other antioxidants\n* Pregnant and lactating women\n* Other rheumatological, inflammatory diseases or malignancies\n* Smokers\n* Thyroid illnesses\n* Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin)",{"count":171,"type":21},118,[24],"The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis.\n\nObjectives :\n\n1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring:\n\n   * Serum Sirtuin 1(SIRT1)\n   * Serum Myeloperoxidase (MPO)\n   * Serum C-reactive protein (CRP)\n2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score).\n3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI).\n4. To assess any adverse effects related to Resveratrol.\n\nPatients:\n\nEligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups:\n\n1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months.\n2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.",[27,175,176,177,178,179,180,181,182],"Rheumatoid Arthritis (RA) Prevention","Inflamation","Antioxidant","Anti Oxidative Stress","Anti Aging","C Reactive Protein","Methotrexate","Quality of Life Outcomes","2025-07-21",{"date":185,"type":38},"2025-07-28",{"date":187,"type":21},"2025-08-01",{"date":189,"type":21},"2026-06-01",{"name":191,"class":45},"Ain Shams University",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":200,"enrollmentInfo":201,"targetDuration":203,"studyType":59,"phases":4,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":46},"100575904","biomarkers-in-inflammatory-rheumatic-diseases-diagnosis-100575904","NCT06778343","Biomarkers in Inflammatory Rheumatic Diseases Diagnosis","BIRDD: Biomarkers in Inflammatory Rheumatic Diseases Diagnosis - Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus","BIRDD","Inclusion Criteria:\n\n* Diagnosis of AS, RA, SLE according the mentioned criteria;\n* Ability to provide informed consent;\n* If entering the study on NSAIDs, tramadol, combination of paracetamol and codeine or hydrocodone, and\u002For non-opioid analgesics, subject must be on stable dose(s) for at least 14 days prior to the screening visit;\n* If entering the study on oral corticosteroids, subject must be on a stable dose of prednisone (≤ 10 mg\u002Fday), or oral corticosteroid equivalents, for at least 14 days prior to the screening visit;\n* If entering the study on MTX, leflunomide, SSZ, and\u002For hydroxychloroquine, subject must be on a stable dose of MTX (≤ 25 mg\u002Fweek) and\u002For SSZ (≤ 3 g\u002Fday) and\u002For hydroxychloroquine (≤ 400 mg\u002Fday) or leflunomide (≤ 20 mg\u002Fday) for at least 28 days prior to the screening visit. A combination of up to two background csDMARDs is allowed;\n* Subject is judged to be in good health as determined by the Principal Investigator based upon the results of medical history, laboratory profile, physical examination, x-Ray performed at the Screening Visit.\n\nExclusion Criteria:\n\n* Current pregnancy or breastfeeding;\n* Prior exposure to any biologic therapy;\n* Intra-articular joint or tendon sheaths injections, spinal\u002Fparaspinal injection(s), or parenteral administration of corticosteroids within 28 days prior to the Baseline Visit. Inhaled or topical corticosteroids are allowed;\n* Receipt of any live vaccine within 4 weeks prior to the screening visit;\n* History of clinically significant (per Investigator\\'s judgment) drug or alcohol abuse within the last 6 months;\n* Subject has a history of inflammatory arthritis of different etiology other than AS, RA or SLE (including but not limited to PsA, mixed connective tissue disease, reactive arthritis, scleroderma, polymyositis, dermatomyositis, fibromyalgia), or any arthritis with onset prior to 17 years of age;\n* Any uncontrolled medical condition (e.g., uncontrolled diabetes mellitus, unstable ischemic heart disease);\n* History of any malignancy;\n* Positive serology for hepatitis B, hepatitis C, or human immunodeficiency virus;\n* Infections requiring hospitalization or intravenous treatment with antibiotics within 30 days or oral treatment with antibiotics within 14 days before enrollment;\n* Note : Healthy Controls should be matched by gender and age. People with acute infections or injuries (in the last 6 months) or non-controlled chronic diseases (cardiac, metabolic, lung, neurologic, gastro-intestinal or renal) will be exclude. Family history of Auto-Immune diseases as diagnosed by a rheumatologist will be also excluded.","65 Years",{"count":202,"type":21},134,"3 Months","Ankylosing spondylitis (AS), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are three diseases where early diagnosis remains a major challenge. However, early diagnosis is the main determinant for a better prognosis. In the early stage, symptoms may be nonspecific and often difficult to establish a differential diagnosis between rheumatic diseases and other diseases, namely infectious and cancer diseases.",[206,27,207],"Ankylosing Spondylitis","Systemic Lupus Erythematosus",[209,210],"Biomarker","Diagnosis","2025-01-16",{"date":213,"type":38},"2025-01-20",{"date":215,"type":38},"2023-01-31",{"date":217,"type":21},"2025-06-30",{"name":219,"class":45},"Universidade Nova de Lisboa",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":227,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":236,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":4},"100571112","manual-diaphragmatic-release-on-ventilatory-functions-in-women-with-rheumatoid-arthritis-100571112","NCT06716008","Manual Diaphragmatic Release on Ventilatory Functions in Women With Rheumatoid Arthritis","Effect of Manual Diaphragmatic Release on Ventilatory Functions in Women With Rheumatoid Arthritis","Inclusion Criteria:\n\n* All women will have rheumatoid arthritis for more than 2 years with low-to-moderate disease activity.\n* Normal to mildly restrictive lung pattern.\n* Their ages will be ranged from 40 to 60 years old.\n* Their body mass index will be less than 30 Kg\u002Fm2.\n\nExclusion Criteria:\n\n* Chronic chest diseases.\n* Recent parenteral steroid administration.\n* Cardiovascular disorders (coronary heart disease, heart failure, cardiac arrhythmia, peripheral arterial disease, uncontrolled hypertension).\n* Smokers.\n* Joint surgery (in the preceding 6 months).\n* Musculoskeletal\u002F neurological limitations to exercise.\n* Pregnancy.","FEMALE","40 Years","60 Years",{"count":231,"type":21},60,[24],"Evaluate the effect of manual diaphragmatic release on ventilatory functions in women with rheumatoid arthritis",[27,235],"Lung Function","NOT_YET_RECRUITING","2024-12-04",{"date":239,"type":38},"2024-12-09",{"date":241,"type":21},"2024-12-03",{"date":243,"type":21},"2025-04-01",{"name":245,"class":45},"Middle East University",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":256,"studyType":59,"phases":4,"briefSummary":257,"conditions":258,"keywords":266,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":46},"100439826","ild-sards-registry-and-biorepository-100439826","NCT05007340","ILD-SARDs Registry and Biorepository","Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (ILD-SARDs) Registry and Biorepository","ILD-SARDs","Inclusion Criteria:\n\n1. Must be aged 18 years or older\n2. Diagnosis of ILD as confirmed by a chest CT\n3. Either a defined SARD, an undifferentiated connective tissue disease or features of autoimmunity without meeting clinical criteria for SARD\n4. Patient must be willing to give their informed consent and must be able to understand and follow the required study procedures.\n\nExclusion Criteria:\n\nN\u002FA",{"count":255,"type":21},252,"5 Years","A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs.\n\nThe purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.",[259,260,261,27,262,263,207,264,265],"Interstitial Lung Disease","Systemic Autoimmune Disease","Rheumatic Diseases","Systemic Sclerosis","Autoimmune Myositis","Usual Interstitial Pneumonia","Nonspecific Interstitial Pneumonia",[259,260,261,27,262,263,207,264,265],"2021-09-01",{"date":269,"type":38},"2021-09-09",{"date":271,"type":38},"2021-08-24",{"date":273,"type":21},"2026-08",{"name":275,"class":45},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre"]